viewAusCann Group Holdings Ltd
The crop is grown in DayaCann’s 30-hectare facility in the south of Santiago, Chile.
() has completed its second harvest with DayaCann joint venture partner Fundación Daya in Chile.
AusCann’s managing director Elaine Darby: “This second harvest in Chile represents an important step in our Chilean operation.
“It is encouraging to see that our medical cannabis can be accessed by patients through the new SAS scheme in Chile whilst clinical studies are progressing.”
READ: AusCann Group gets regulatory nod to supply medicinal cannabis products in Chile
Fundación Daya has worked with the Chilean National Institute of Public Health to establish a special access scheme (SAS) which enables patients in Chile access to local medicinal cannabis product.
The medical cannabis product in Chile’s SAS is being locally manufactured at Knop Laboratories from cannabis supplied by DayaCann.
Harvest yielded over 50% more than first crop
The second crop yielded 620 kilograms of dried cannabis product, an increase of over 50% on the 400 kilograms yielded from the first crop.
This equates to a yield of about 1.2 tonnes per hectare.
First-mover following legislative change
AusCann sees the South American market as internationally significant following recent legislative changes in Argentina, which has joined Chile, Colombia and Uruguay in legalising medical cannabis for therapeutic purposes.
ASX:AC8
Market: ASX
Market Cap: $93.53 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Auscann targeting pain management with Australian cannabinoid products
Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....
on 09/05/2018
2 min read
Prev article
2 min read
